Mettler-Toledo International Inc. (MTD): what the price assumes

In the published model solve dated 2026-Q2, anchored at $1398.58, Mettler-Toledo International Inc. (MTD) is priced for +30.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/MTD

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.9% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.7%); the inversion above states its own rate.

Per-Model Detail (n=12)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Mettler-Toledo makes precision instruments for labs, factories, and retailers, and its real moat is the service organization of roughly 9,300 people the 10-K calls among the "broadest global sales and service organizations among precision instrument manufacturers" it competes against.
• The biggest risk is the gap between price and pace: the stock embeds something near 30% annual operating-income growth while management guides full-year local-currency sales growth of about 4%.
• Watch the second-half acceleration management expects from China and India, and the pace of buybacks, which have driven the share count steadily lower but also left the company with negative book equity.

Bull Case

What the market is paying for here is quality and consistency, and Mettler-Toledo has both in unusual measure. The price reflects a business that earns a roughly 23% operating margin, converts profit to free cash flow reliably, and dominates a set of niches where being the trusted instrument is worth a premium. A pharmaceutical lab weighing active ingredients to the microgram, a food producer checking package weights against regulation, a factory measuring product on the line, all rely on instruments where accuracy is not negotiable, and Mettler-Toledo is the name that owns those niches. The 10-K describes a company manufacturing "a wide variety of precision instruments" backed by one of the broadest sales-and-service organizations in the field, roughly 9,300 people. That service network is the moat: it gets the company into the customer's facility, keeps the installed base running, and generates recurring service and consumables revenue that compounds.

The recent results show the model working even in a soft demand environment. First-quarter 2026 sales rose 7% to $947 million, with growth across all regions in local currency and particular strength in industrial and food-retailing products. Management raised full-year adjusted earnings guidance and pointed to improving pipeline momentum, citing emerging-market growth in China and India as the driver of an expected second-half acceleration. China's full-year growth expectation was lifted to mid-single digit on core industrial and automation demand. For a company with this much exposure to capital spending and lab budgets, signs of a demand recovery are exactly what the bull case needs.

Capital allocation is relentless and shareholder-friendly. Free cash flow near $790 million funds a steady buyback that has shrunk the share count at roughly 3% a year, concentrating each remaining holder's claim on a growing earnings stream. Mettler-Toledo has compounded earnings per share for years through the combination of mid-single-digit organic growth, margin expansion, and share reduction, and the franchise economics, high margins, recurring revenue, and pricing power, are what justify the market treating it as a premium compounder. The bull case is that the demand recovery extends the growth runway and the buyback keeps doing the rest.

Bear Case

The bear case starts with capital allocation, because Mettler-Toledo's relentless buyback has produced a balance sheet that should give a buyer pause. Years of repurchasing stock above book value have driven the company's book equity negative, which is why the asset-value valuation methods cannot even run here. There is nothing inherently wrong with returning cash, and the buyback has genuinely lifted per-share earnings, but a company that has bought back so much stock that it carries negative equity has less balance-sheet flexibility than its quality reputation suggests, and it has been funding part of that return with debt. Net debt sits near $2.2 billion against thin liquid assets, covered comfortably by earnings at 13.5 times interest, but the cushion is the cash flow, not the balance sheet.

The harder problem is the price against the pace. At roughly 29x operating income, the market is paying for something close to 30% annual operating-income growth sustained for five years. Management's own guidance is for about 4% local-currency sales growth for the full year. Even allowing for margin expansion and the buyback's contribution to per-share growth, the gap between an implied ~30% and a guided ~4% is the central risk. The assumed pace runs well above what the company has historically delivered, and only about 27% of comparable fast-growers have sustained that kind of growth even five years. A premium compounder is a fine thing to own; paying for hypergrowth from a steady mid-single-digit grower is a different proposition.

The demand backdrop carries real cyclicality the price does not discount. Mettler-Toledo sells capital equipment, and the 10-K is direct that in a downturn customers "decrease or delay capital expenditures" and may buy "lower-cost products made by competitors and not resume purchasing our products even after economic conditions improve". China is a swing factor in both directions, and the recovery management expects is a forecast, not a fact. None of the valuation methods reach the current price: the earnings-power lens lands near $315 on a zero-growth basis, and even the relative-multiple method at the sector P/E lands near $827, well below the price. When no standard frame reaches the price, the premium rests entirely on execution continuing at a level above the company's track record.

Valuation

At $1,145 (June 27, 2026), Mettler-Toledo's price makes a demanding bet. Inverted, it implies company-wide operating growth near 31% a year for five years, a pace that runs well above what the company has historically delivered and that management's own guidance, around 4% local-currency sales growth, does not approach. The framework labels the embedded assumption high, and the history is sobering: only about 27% of comparable fast-growers have sustained that growth for five years. This is a quality business priced for a growth rate that quality alone does not produce.

The valuation methods are unusual here because the company's negative book equity, a product of years of buybacks above book, leaves the asset-value lens unable to run. What remains says expensive. The earnings-power family lands far below the price, with FCF Yield near $316 on a zero-growth perpetuity and the SBC-adjusted version near $304. The single relative-multiple method, at an 18x sector P/E, lands near $827, still well under the price. No valuation family reaches $1,145. That is the honest signal: the price is a bet beyond what any standard method supports, sustained by the market's willingness to pay a premium for a franchise it trusts to keep compounding earnings per share.

The peer comparison frames how much of a premium that is. The scientific-instruments cohort includes Danaher, Waters, and Veralto, high-quality names that also trade at premium multiples, and within that group Mettler-Toledo sits in the lower half of the peer multiple range, which is the one piece of relative comfort in an otherwise stretched picture. The build of the franchise is the better justification than any single multiple: recurring service revenue, pricing power, and a ~23% operating margin support a richer multiple than a pure-cyclical would warrant. The decisive variable is durability: whether the service-driven, recurring-revenue model can hold mid-single-digit organic growth long enough, with the buyback amplifying it, to grow into a price the methods currently call rich.

Catalysts

The first-quarter 2026 results, reported May 7, set the recent tone. Mettler-Toledo posted sales of $947.1 million, up 7%, with growth across all regions in local currency led by industrial and food-retailing products, though revenue came in just shy of estimates. The company raised its full-year adjusted earnings guidance while reiterating roughly 4% local-currency sales growth. The combination of an earnings beat and a guidance raise on steady top-line growth is the standard shape for this quality compounder.

The forward catalyst management emphasized is a second-half acceleration. The company cited improving pipeline momentum and emerging-market growth, particularly in China and India, and lifted its China full-year expectation to mid-single-digit growth on core industrial and automation demand. China has been the swing region for the precision-instruments group, so any sustained recovery there is the most direct upside to the growth story. The pace of that recovery is what determines whether the second-half acceleration management expects actually arrives.

The steady catalyst underneath is capital return. Free cash flow funds an ongoing buyback that continues to reduce the share count, the mechanism that has driven much of the company's per-share earnings growth over time. The next quarterly print is the test of whether the regional momentum, especially in China and India, builds as management expects, and whether the full-year guidance proves conservative or optimistic.

Peer Cohorts (Per Segment, With Filing Citations)

U.S. Operations / Swiss Operations +3 more (reported)

• A (AGILENT TECHNOLOGIES, INC.)
• FY2025 10-K: …http://fasb.org/us-gaap/2025#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2025#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2025#SellingGeneralAndAdministrativeExpense iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure a:contracts a:numberOfCustomers a:segement 0001090872…
• FY2025 10-K: …2024-11-01 2025-10-31 0001090872 us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2024-11-01 2025-10-31 0001090872 us-gaap:AccumulatedTranslationAdjustmentMember 2025-10-31 0001090872 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2025-10-31 0001090872…
• DHR (Danaher Corporation)
• FY2025 10-K: …States foreign policy and national security considerations; and • the import regulatory activities of the U.S. Customs and Border Protection and other U.S. government agencies. Other nations' governments have implemented similar export/import control and economic sanction regulations, which may affect the Company's…
• FY2025 10-K: -gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:BiotechnologySegmentMember 2023-01-01 2023-12-31 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:LifeSciencesSegmentMember 2023-01-01 2023-12-31 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember…
• MKSI (MKS INC)
• FY2025 10-K: …a trade war or other governmental action related to tariffs or trade agreements or policies, has the potential to adversely impact demand for our products, our costs, our customers, our suppliers and the world and U.S. economies, which in turn could have a material adverse effect on our business, operating results…
• FY2025 10-K: 10-K FY 0001049502 false P10Y P3Y P3Y P3Y P1Y P8Y http://fasb.org/us-gaap/2025#Liabilities http://fasb.org/us-gaap/2025#Liabilities http://fasb.org/us-gaap/2025#Liabilities http://fasb.org/us-gaap/2025#Liabilities http://fasb.org/us-gaap/2025#Liabilities http://fasb.org/us-gaap/2025#Liabilities…
• AME (AMETEK, Inc.)
• FY2025 10-K: 06 2025-02-06 0001037868 us-gaap:SubsequentEventMember 2026-02-12 0001037868 us-gaap:SubsequentEventMember 2026-02-12 2026-02-12 0001037868 us-gaap:SubsequentEventMember 2026-02-11 2026-02-11 0001037868 2025-10-01 2025-12-31 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549…
• FY2025 10-K: …ame:ElectromechanicalGroupMember 2024-01-01 2024-12-31 0001037868 us-gaap:OperatingSegmentsMember ame:ElectronicInstrumentsGroupMember 2024-01-01 2024-12-31 0001037868 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001037868 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-12-31 0001037868…
• ROP (ROPER TECHNOLOGIES INC)
• FY2025 10-K: -12-31 0000882835 rop:RIPICTopCoMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember rop:IndustrialBusinessesMember 2025-12-31 0000882835 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember rop:IndustrialBusinessesMember 2025-01-01 2025-12-31 0000882835 rop:RIPICTopCoMember…
• FY2025 10-K: …rop:NetworkSoftwareAndSystemsSegmentMember 2024-12-31 0000882835 us-gaap:OperatingSegmentsMember rop:TechnologyEnabledProductsSegmentMember 2024-12-31 0000882835 us-gaap:CorporateNonSegmentMember 2024-12-31 0000882835 us-gaap:OperatingSegmentsMember rop:ApplicationSoftwareSegmentMember 2023-01-01 2023-12-31…
• VNT (Vontier Corporation)
• FY2025 10-K: …us-gaap:ProductMember vnt:EnvironmentalFuelingSolutionsSegmentMember 2025-01-01 2025-12-31 0001786842 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember vnt:MobilityTechnologiesSegmentMember 2025-01-01 2025-12-31 0001786842 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember vnt:RepairSolutionsSegmentMember…
• FY2025 10-K: …such, significant uncertainty around future tariff policies remains. We import inventory into the United States from a number of countries, and as such, if tariffs remain in effect for a prolonged period of time, we expect our cost to import inventory into the United States to increase. We have actively managed our…
• VLTO (VERALTO CORPORATION)
• FY2025 10-K: -12-31 0001967680 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember vlto:ProductAndQualityInnovationSegmentMember 2025-01-01 2025-12-31 0001967680 srt:NorthAmericaMember 2025-01-01 2025-12-31 0001967680 us-gaap:OperatingSegmentsMember vlto:WesternEuropeMember vlto:WaterQualitySegmentMember 2025-01-01 2025-12-31…
• FY2025 10-K: 967680 srt:ReportableGeographicalComponentsMember us-gaap:GeographicConcentrationRiskMember us-gaap:PropertyPlantAndEquipmentMember 2025-01-01 2025-12-31 0001967680 srt:ReportableGeographicalComponentsMember us-gaap:GeographicConcentrationRiskMember us-gaap:PropertyPlantAndEquipmentMember 2024-01-01 2024-12-31…
• FTV (Fortive Corp)
• FY2025 10-K: AmericaMember 2025-01-01 2025-12-31 0001659166 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-12-31 0001659166 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-12-31 0001659166…
• FY2025 10-K: …2025-01-01 2025-12-31 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-12-31 0001659166 ftv:EnergyAndInfrastructureMember 2025-01-01 2025-12-31 0001659166 us-gaap:OperatingSegmentsMember ftv:EnergyAndInfrastructureMember…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.